In 2023, Liam et al. published the final results of a randomized phase II INSIGHT trial [97] conducted in patients with advanced or metastatic NSCLC with EGFR mutations and with acquired MET dysregulation who progressed after the first-line treatment with the first or second generation of EGFR inhibitors. Here, MET is linked to non-small cell lung carcinoma.